Genferon® Light (Genferon Lite)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbspnasal dosing spray
Composition:

1 dose of the drug contains:

active substances: interferon alfa-2b human recombinant 50,000 IU, taurine 1.0 mg.

Excipients: disodium edetate dihydrate 0.02 mg, glycerol 7.0 mg, dextran 40,000 2.4 mg, polysorbate 80 1.0 mg, sodium chloride 0.8 mg, potassium chloride 0.02 mg, sodium hydrogen phosphate dodecahydrate 0.115 mg, potassium dihydrogen phosphate 0.02 mg, peppermint oil 0.01 mg, methyl parahydroxybenzoate 0.02 mg, water for injection is sufficient.

Description:Transparent colorless or light yellow liquid, with no visible mechanical impurities.
Pharmacotherapeutic group:Immunomodulating agents, interferons
ATX: & nbsp
  • Interferon alfa-2b
    • Pharmacodynamics:

    The composition of the preparation GENFERON® LITE is recombinant human interferon alpha-2b, produced by the bacterium strain Escherichia coli, into which the gene of interferon alpha-2 was introduced by genetic engineering methodsb rights.

    Interferon alfa-2b has antiviral, immunomodulating, antiproliferative and antibacterial action. The antiviral effect is mediated by the activation of a number of intracellular enzymes that inhibit the replication of viruses. Immunomodulating effect is manifested, first of all,intensification of cell-mediated immune system reactions, which increases the effectiveness of the immune response against viruses, intracellular parasites and cells that underwent tumor transformation. This is achieved through activation Cd8+ T-killers, NKcells (natural killers), enhancing the differentiation of B-lymphocytes and their production of antibodies, activation of the monocyte-macrophage system and phagocytosis, as well as increasing the expression of the molecules of the main histocompatibility complex of type I, which increases the probability of recognition of infected cells by immune system cells. Activation under the influence of interferon leukocytes contained in all layers of the mucous membrane, ensures their active participation in the elimination of pathological foci; in addition, due to the influence of interferon, the production of secretory immunoglobulin A is restored. The antibacterial effect is mediated by immune system reactions, enhanced by interferon.

    Taurine contributes to the normalization of metabolic processes and tissue regeneration, has a membrane-stabilizing and immunomodulating effect. Being a strong antioxidant, taurine directly interacts with the active forms of oxygen, the excessive accumulation of which contributes to the development of pathological processes. Taurine promotes the preservation of the biological activity of interferon, enhancing the therapeutic effect of the drug.

    Pharmacokinetics:

    With intranasal application due to the high concentration in the focus of infection, a pronounced local antiviral and immunostimulating effect is achieved. Systemic absorption of the drug is insignificant - low bioavailability of drugs with intranasal administration is associated with the functioning of a special family of proteins from the 25 proteins that make up the mucous membrane of the nasal cavity and control the transport of all molecular and cellular objects penetrating the mucosa.

    At the same time, a certain amount of the drug enters the systemic circulation, thereby achieving a systemic immunomodulatory effect.

    Indications:

    Prevention and treatment of influenza and ARVI in adults and children older than 14 years.

    Contraindications:

    Hypersensitivity to interferon alpha-2b or other components of the drug. Children up to 14 years.

    Carefully:

    Caution should be given to patients with nasal bleeding.

    Pregnancy and lactation:

    Allowed to be used throughout the period of pregnancy.

    Dosing and Administration:

    The drug is administered intranasally by aerosol administration of 1 dose (1 dose = 1 short press on the dispenser).

    At the first sign of the disease, GENFERON® LITE is administered intranasally for 5 days at a single dose (one push on the dispenser) to each nasal passage 3 times a day (one dose approximately 50,000 ME interferon alpha, daily should not exceed 500 000 ME).

    When in contact with an acute respiratory viral infection and / or during supercooling, the drug is administered according to the indicated scheme 2 times a day for 5-7 days. If necessary, preventive courses are repeated.

    Instructions for using the spray:

    1 Remove the protective cap.

    2 Before use for the first time, press the dispenser several times until a thin jet appears.

    3 When using, keep the bottle in an upright position.

    4 Carry out the injection of the drug with a single push on the dispenser in each nasal turn alternately.

    5 After use, cover the dispenser with a protective cap.

    To avoid the spread of infection, individual use is recommended.
    Side effects:Side effects with the preparation of GENFERON® LITE were not noted.
    Overdose:

    In cases of overdose of the drug GENFERON® LITE was not reported.

    Interaction:Not noted.
    Form release / dosage:Spray nasal dosed 50 000 IU + 1 mg / dose.
    Packaging:

    For 100 doses per bottle of dark glass, sealed with a dispenser with a protective cap. By 1 A bottle with instructions for use in a pack of cardboard.

    Storage conditions:

    Store and transport in a dry, dark place at a temperature of 2 to 8 ° C.

    Keep out of the reach of children.

    Shelf life:

    2 years.

    Do not use after the expiration date stated on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-009046/10
    Date of registration:31.08.2010
    Expiration Date:Unlimited
    The owner of the registration certificate:BIOCAD, CJSC BIOCAD, CJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp24.03.2017
    Illustrated instructions
    Instructions
    Up